Jundishapur Journal of Microbiology

Published by: Kowsar

Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?

Zohreh Aminzadeh 1 , 2 , Davood Yadegarynia 1 , Alireza Fatemi 1 , * , Elham Tahmasebian Dehkordi 1 and Saeed Azad Armaki 1
Authors Information
1 Infectious Diseases and Tropical Medicine Research Center, Shahid Beheshti University of Medical Sciences, Tehran, IR Iran
2 University of Queensland Centre for Clinical Research, The University of Queensland, Brisbane, Australia
Article information
  • Jundishapur Journal of Microbiology: October 01, 2014, 7 (10); e12831
  • Published Online: October 1, 2014
  • Article Type: Brief Report
  • Received: June 11, 2013
  • Revised: July 8, 2013
  • Accepted: July 11, 2013
  • DOI: 10.5812/jjm.12831

To Cite: Aminzadeh Z, Yadegarynia D, Fatemi A, Tahmasebian Dehkordi E, Azad Armaki S. Vancomycin Minimum Inhibitory Concentration for Methicillin-Resistant Staphylococcus aureus Infections; Is There Difference in Mortality Between Patients?, Jundishapur J Microbiol. 2014 ; 7(10):e12831. doi: 10.5812/jjm.12831.

Copyright © 2014, Ahvaz Jundishapur University of Medical Sciences. This is an open-access article distributed under the terms of the Creative Commons Attribution-NonCommercial 4.0 International License (http://creativecommons.org/licenses/by-nc/4.0/) which permits copy and redistribute the material just in noncommercial usages, provided the original work is properly cited.
1. Background
2. Objectives
3. Patients and Methods
4. Results
5. Discussion
  • 1. Hidayat LK, Hsu DI, Quist R, Shriner KA, Wong-Beringer A. High-dose vancomycin therapy for methicillin-resistant Staphylococcus aureus infections: efficacy and toxicity. Arch Intern Med. 2006; 166(19): 2138-44[DOI][PubMed]
  • 2. National Nosocomial Infections Surveillance S. National Nosocomial Infections Surveillance (NNIS) System Report, data summary from January 1992 through June 2004, issued October 2004. Am J Infect Control. 2004; 32(8): 470-85[DOI][PubMed]
  • 3. Shukla SK. Community-associated methicillin-resistant Staphylococcus aureus and its emerging virulence. Clin Med Res. 2005; 3(2): 57-60[PubMed]
  • 4. Stevens DL. The role of vancomycin in the treatment paradigm. Clin Infect Dis. 2006; 42 Suppl 1-7[DOI][PubMed]
  • 5. Hiramatsu K, Aritaka N, Hanaki H, Kawasaki S, Hosoda Y, Hori S, et al. Dissemination in Japanese hospitals of strains of Staphylococcus aureus heterogeneously resistant to vancomycin. Lancet. 1997; 350(9092): 1670-3[DOI][PubMed]
  • 6. Clinical and Laboratory Standards Institute (CLSI) . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically; approved standard . 2006;
  • 7. Soriano A, Marco F, Martinez JA, Pisos E, Almela M, Dimova VP, et al. Influence of vancomycin minimum inhibitory concentration on the treatment of methicillin-resistant Staphylococcus aureus bacteremia. Clin Infect Dis. 2008; 46(2): 193-200[DOI][PubMed]
  • 8. Sakoulas G, Moise-Broder PA, Schentag J, Forrest A, Moellering RJ, Eliopoulos GM. Relationship of MIC and bactericidal activity to efficacy of vancomycin for treatment of methicillin-resistant Staphylococcus aureus bacteremia. J Clin Microbiol. 2004; 42(6): 2398-402[DOI][PubMed]
  • 9. Lodise TP, Graves J, Evans A, Graffunder E, Helmecke M, Lomaestro BM, et al. Relationship between vancomycin MIC and failure among patients with methicillin-resistant Staphylococcus aureus bacteremia treated with vancomycin. Antimicrob Agents Chemother. 2008; 52(9): 3315-20[DOI][PubMed]
  • 10. Charles PG, Ward PB, Johnson PD, Howden BP, Grayson ML. Clinical features associated with bacteremia due to heterogeneous vancomycin-intermediate Staphylococcus aureus. Clin Infect Dis. 2004; 38(3): 448-51[DOI][PubMed]
  • 11. Maor Y, Hagin M, Belausov N, Keller N, Ben-David D, Rahav G. Clinical features of heteroresistant vancomycin-intermediate Staphylococcus aureus bacteremia versus those of methicillin-resistant S. aureus bacteremia. J Infect Dis. 2009; 199(5): 619-24[DOI][PubMed]
  • 12. Clinical and Laboratory Standards Institute . Methods for dilution antimicrobial susceptibility tests for bacteria that grow aerobically, approved standard. 2012;
  • 13. Pastagia M, Kleinman LC, Lacerda de la Cruz EG, Jenkins SG. Predicting risk for death from MRSA bacteremia. Emerg Infect Dis. 2012; 18(7): 1072-80[DOI][PubMed]
  • 14. Takesue Y, Nakajima K, Takahashi Y, Ichiki K, Ishihara M, Wada Y, et al. Clinical characteristics of vancomycin minimum inhibitory concentration of 2 mug/ml methicillin-resistant Staphylococcus aureus strains isolated from patients with bacteremia. J Infect Chemother. 2011; 17(1): 52-7[DOI][PubMed]
  • 15. van Hal SJ, Jones M, Gosbell IB, Paterson DL. Vancomycin heteroresistance is associated with reduced mortality in ST239 methicillin-resistant Staphylococcus aureus blood stream infections. PLoS One. 2011; 6(6)[DOI][PubMed]
  • 16. van Hal SJ, Lodise TP, Paterson DL. The clinical significance of vancomycin minimum inhibitory concentration in Staphylococcus aureus infections: a systematic review and meta-analysis. Clin Infect Dis. 2012; 54(6): 755-71[DOI][PubMed]
  • 17. Yusof A, Engelhardt A, Karlsson A, Bylund L, Vidh P, Mills K, et al. Evaluation of a new Etest vancomycin-teicoplanin strip for detection of glycopeptide-intermediate Staphylococcus aureus (GISA), in particular, heterogeneous GISA. J Clin Microbiol. 2008; 46(9): 3042-7[DOI][PubMed]
  • 18. Sharpe JN, Shively EH, Polk HC, Jr. Clinical and economic outcomes of oral linezolid versus intravenous vancomycin in the treatment of MRSA-complicated, lower-extremity skin and soft-tissue infections caused by methicillin-resistant Staphylococcus aureus. Am J Surg. 2005; 189(4): 425-8[DOI][PubMed]
  • 19. Weigelt J, Itani K, Stevens D, Lau W, Dryden M, Knirsch C, et al. Linezolid versus vancomycin in treatment of complicated skin and soft tissue infections. Antimicrob Agents Chemother. 2005; 49(6): 2260-6[DOI][PubMed]
  • 20. Stryjewski ME, O'Riordan WD, Lau WK, Pien FD, Dunbar LM, Vallee M, et al. Telavancin versus standard therapy for treatment of complicated skin and soft-tissue infections due to gram-positive bacteria. Clin Infect Dis. 2005; 40(11): 1601-7[DOI][PubMed]
Creative Commons License Except where otherwise noted, this work is licensed under Creative Commons Attribution Non Commercial 4.0 International License .

Search Relations:



Create Citiation Alert
via Google Reader

Readers' Comments